(Cell Reports 35, 108944-1–16.e1–e6; April 6, 2021) Carlos Arteaga receives or has received research grants from Pfizer, Lilly, and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. None of these relationships are relevant to the work published in this manuscript. This information was inadvertently omitted during the preparation of the manuscript but now appears with the article online. The authors regret this error.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)